Literature DB >> 28960259

Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.

Elizabeth Shurell1, Cristina Olcese1, Sujata Patil2, Beryl McCormick3, Kimberly J Van Zee1, Melissa L Pilewskie1.   

Abstract

BACKGROUND: The current study was conducted to examine the association between ipsilateral breast tumor recurrence (IBTR) and the timing of radiotherapy (RT) in women with ductal carcinoma in situ (DCIS) undergoing breast-conserving surgery (BCS).
METHODS: Women with DCIS who were treated with BCS and RT from 1980 through 2010 were identified from a prospectively maintained database. IBTR rates, measured from the time of RT completion, were compared between those who initiated RT ≤8 weeks, >8 to 12 weeks, and >12 weeks after the completion of surgery. The association between RT timing and IBTR was evaluated by Kaplan-Meier and log-rank analyses; Cox modeling was used for multivariable analysis.
RESULTS: A total of 1323 women met the inclusion criteria. The median follow-up was 6.6 years, with 311 patients followed for ≥10 years. A total of 126 IBTR events occurred. Patients were categorized by RT timing: 806 patients (61%) with timing of ≤8 weeks, 386 patients (29%) with timing of >8 to 12 weeks, and 131 patients (10%) with timing >12 weeks. The 5-year and 10-year IBTR rates were 5.8% and 13.0%, respectively, for RT starting ≤8 weeks after surgery; 3.8% and 7.6%, respectively, for RT starting >8 to 12 weeks after surgery; and 8.8% and 23.0%, respectively, for an RT delay >12 weeks after surgery (P = .004). On multivariable analysis, menopause (hazard ratio [HR], 0.54; P = .0009) and endocrine therapy (HR, 0.45; P = .002) were found to be protective against IBTR, whereas a delay in RT >12 weeks compared with ≤8 weeks was associated with a higher risk of IBTR (HR, 1.92; P = .014). There was no difference in IBTR noted between RT initiation at ≤8 weeks and initiation at >8 to 12 weeks after BCS (P = .3).
CONCLUSIONS: A delay in RT >12 weeks is associated with a significantly higher risk of IBTR in women undergoing BCS for DCIS. Efforts should be made to avoid delays in starting RT to minimize the risk of disease recurrence. Cancer 2018;124:46-54.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  breast cancer; ductal carcinoma in situ; radiotherapy; recurrence

Mesh:

Substances:

Year:  2017        PMID: 28960259      PMCID: PMC5734990          DOI: 10.1002/cncr.30972

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ.

Authors:  Udo Rudloff; Lindsay M Jacks; Jessica I Goldberg; Christine A Wynveen; Edi Brogi; Sujata Patil; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

2.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

Authors:  Steven A Narod; Javaid Iqbal; Vasily Giannakeas; Victoria Sopik; Ping Sun
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

3.  Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial.

Authors:  Fredrik Wärnberg; Hans Garmo; Stefan Emdin; Veronica Hedberg; Linda Adwall; Kerstin Sandelin; Anita Ringberg; Per Karlsson; Lars-Gunnar Arnesson; Harald Anderson; Karin Jirström; Lars Holmberg
Journal:  J Clin Oncol       Date:  2014-10-13       Impact factor: 44.544

4.  Nationwide trends in mastectomy for early-stage breast cancer.

Authors:  Kristy L Kummerow; Liping Du; David F Penson; Yu Shyr; Mary A Hooks
Journal:  JAMA Surg       Date:  2015-01       Impact factor: 14.766

5.  The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis.

Authors:  Joan L Warren; Donald L Weaver; Therese Bocklage; Charles R Key; Charles E Platz; Kathleen A Cronin; Rachel Ballard-Barbash; Shawna C Willey; Linda C Harlan
Journal:  Cancer       Date:  2005-11-01       Impact factor: 6.860

6.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

Authors:  Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2011-03-11       Impact factor: 13.506

7.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.

Authors:  B Fisher; J Costantino; C Redmond; E Fisher; R Margolese; N Dimitrov; N Wolmark; D L Wickerham; M Deutsch; L Ore
Journal:  N Engl J Med       Date:  1993-06-03       Impact factor: 91.245

Review 8.  Optimal timing for adjuvant radiation therapy in breast cancer: a comprehensive review and perspectives.

Authors:  Pelagia G Tsoutsou; Michael I Koukourakis; David Azria; Yazid Belkacémi
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-14       Impact factor: 6.312

Review 9.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Authors:  C Correa; P McGale; C Taylor; Y Wang; M Clarke; C Davies; R Peto; N Bijker; L Solin; S Darby
Journal:  J Natl Cancer Inst Monogr       Date:  2010

10.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Authors:  Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George
Journal:  Lancet Oncol       Date:  2010-12-07       Impact factor: 41.316

View more
  10 in total

1.  Delayed initiation of radiation therapy is associated with inferior outcomes for breast cancer patients with hormone receptor-negative tumors after breast-conserving surgery.

Authors:  Xiaoyan Ma; Jie Chen; Ding Ma; Yizhou Jiang; Zhebin Liu; Sheng Chen; Ying Zhang; Yizhou Shen; Xiaoli Yu; Zhaozhi Yang; Shuang Li; Miao Mo; Yongxiang Qian; Guangyu Liu; Jiong Wu; Zhiming Shao; Keda Yu; Genhong Di
Journal:  Gland Surg       Date:  2021-09

2.  Rapid Adaptation of Breast Radiation Therapy Use During the Coronavirus Disease 2019 Pandemic at a Large Academic Cancer Center in Canada.

Authors:  Christine A Koch; Grace Lee; Zhihui A Liu; Fei-Fei Liu; Anthony Fyles; Kathy Han; Aisling Barry; Jennifer Croke; Danielle Rodin; Joelle Helou; Ezra Hahn; Naghmeh Isfahanian; Jane DeRocchis; Susanne Lofgren; Thomas G Purdie
Journal:  Adv Radiat Oncol       Date:  2020-06-19

Review 3.  Radiotherapy waiting time in Northern Nigeria: experience from a resource-limited setting.

Authors:  Nuhu Tumba; Sunday Adeyemi Adewuyi; Kelechi Eguzo; Adeniyi Adenipekun; Rasaaq Oyesegun
Journal:  Ecancermedicalscience       Date:  2020-09-04

4.  Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic.

Authors:  Pranshu Mohindra; Sushil Beriwal; Mitchell Kamrava
Journal:  Brachytherapy       Date:  2020-05-01       Impact factor: 2.362

5.  Polygon method: A systematic margin assessment for breast conservation.

Authors:  Shu Ichihara; Suzuko Moritani; Rieko Nishimura; Mikinao Oiwa; Takako Morita; Takako Hayashi; Aya Kato; Tokiko Endo; Akiko Kada; Noriko Ito; Tetsuo Kuroishi; Yasuyuki Sato
Journal:  Cancer Med       Date:  2019-05-07       Impact factor: 4.452

6.  COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.

Authors:  Vonetta M Williams; Jenna M Kahn; Matthew M Harkenrider; Junzo Chino; Jonathan Chen; L Christine Fang; Emily F Dunn; Emma Fields; Jyoti S Mayadev; Ramesh Rengan; Daniel Petereit; Brandon A Dyer
Journal:  Brachytherapy       Date:  2020-04-21       Impact factor: 2.362

7.  A Call for a Radiation Oncology Model Based on New 4R's During the COVID-19 Pandemic.

Authors:  Shrinivas Rathod; Arbind Dubey; Amitava Chowdhury; Bashir Bashir; Rashmi Koul
Journal:  Adv Radiat Oncol       Date:  2020-04-25

8.  Influence of Adjuvant Radiotherapy Timing on Survival Outcomes in High-Risk Patients Receiving Neoadjuvant Treatments.

Authors:  Lu Cao; Cheng Xu; Meng-Di Wang; Wei-Xiang Qi; Gang Cai; Rong Cai; Shu-Bei Wang; Dan Ou; Min Li; Kun-Wei Shen; Jia-Yi Chen
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

Review 9.  Radiation oncology in times of COVID-2019: A review article for those in the eye of the storm - An Indian perspective.

Authors:  Ritika Harjani Hinduja; Karishma George; Mansi Barthwal; Vibhay Pareek
Journal:  Semin Oncol       Date:  2020-07-13       Impact factor: 4.929

Review 10.  Breast Radiation Therapy Under COVID-19 Pandemic Resource Constraints-Approaches to Defer or Shorten Treatment From a Comprehensive Cancer Center in the United States.

Authors:  Lior Z Braunstein; Erin F Gillespie; Linda Hong; Amy Xu; Samuel F Bakhoum; John Cuaron; Boris Mueller; Beryl McCormick; Oren Cahlon; Simon Powell; Atif J Khan
Journal:  Adv Radiat Oncol       Date:  2020-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.